thalidomide has been researched along with Blood Diseases in 48 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity." | 9.19 | Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 9.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 7.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 7.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 7.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 7.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 7.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| " Phase 2 dosing was determined to be bortezomib 1." | 6.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 5.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| " In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI." | 5.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity." | 5.19 | Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. ( Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB, 2014) |
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance." | 5.15 | Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation." | 4.89 | Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. ( Baldi, I; Beksac, M; Boccadoro, M; Ciccone, G; Galli, M; Gay, F; Gimsing, P; Hulin, C; Juliusson, G; Kolb, B; Leleu, X; Lokhorst, H; Palumbo, A; Pégourié, B; Pezzatti, S; Rodon, P; Rolke, J; Schaafsma, M; Sonneveld, P; Sucak, G; Turesson, I; van der Holt, B; Waage, A; Wetterwald, M; Wijermans, P; Zweegman, S, 2013) |
| "The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide and bortezomib, has expanded treatment options for patients with multiple myeloma." | 4.86 | Management of treatment-related adverse events in patients with multiple myeloma. ( Mateos, MV, 2010) |
| " Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases." | 4.84 | [Novel medical treatment modalities in hematology]. ( Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A, 2008) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 3.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program." | 3.80 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. ( Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS, 2014) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 3.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 3.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 3.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "Between April 2006 and June 2009, 34 newly diagnosed patients with multiple myeloma received one to three courses of bortezomib 1." | 3.76 | Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ( Alexanian, R; Delasalle, K; Giralt, S; Wang, M, 2010) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| " Phase 2 dosing was determined to be bortezomib 1." | 2.75 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010) |
| "Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL)." | 2.73 | Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. ( Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB, 2008) |
| "Treatments for refractory metastatic renal cell cancer (RCC) are limited." | 2.73 | Lenalidomide therapy for metastatic renal cell carcinoma. ( Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S, 2008) |
| "Disease progression was observed in 14 (45%) patients." | 2.73 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age." | 2.53 | Nuances in the Management of Older People With Multiple Myeloma. ( Ailawadhi, S; Gay, F; Larocca, A; Pawlyn, C; Roy, V, 2016) |
| "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications." | 2.50 | [Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014) |
| "in pediatric patients with brainstem tumors." | 2.46 | [Thalidomide in oncological and hematological diseases]. ( Anttila, P; Kivivuori, SM, 2010) |
| "Lenalidomide has already been approved for the management of low or intermediate-1 risk myelodysplastic syndrome with chromosome 5q31 deletion and relapsed/refractory multiple myeloma in combination with dexamethasone." | 2.46 | Lenalidomide: a synthetic compound with an evolving role in cancer management. ( Grivas, PD; Saloura, V, 2010) |
| "Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen combining melphalan and prednisone (MP)." | 2.45 | How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. ( Gay, F; Palumbo, A, 2009) |
| "Four patients died due to disease progression and 17 were found to have progressed after ASCT (the median progression-free survival after ASCT was 19." | 1.40 | Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. ( Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST, 2014) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 1.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| " In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI." | 1.36 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010) |
| "Thalidomide was first administered at 100 mg/day p." | 1.33 | The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. ( Aivado, M; Fenk, R; Gattermann, N; Germing, U; Haas, R; Hünerlitürkoglu, A; Kobbe, G; Kündgen, A; Strupp, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 14 (29.17) | 29.6817 |
| 2010's | 31 (64.58) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, HS | 1 |
| Kim, K | 3 |
| Kim, SJ | 3 |
| Lee, JJ | 2 |
| Kim, I | 1 |
| Kim, JS | 2 |
| Eom, HS | 2 |
| Yoon, DH | 1 |
| Suh, C | 2 |
| Shin, HJ | 1 |
| Mun, YC | 2 |
| Kim, MK | 1 |
| Lim, SN | 1 |
| Choi, CW | 1 |
| Kang, HJ | 1 |
| Yoon, SS | 2 |
| Min, CK | 2 |
| Nakazato, T | 1 |
| Hagihara, M | 1 |
| Sahara, N | 1 |
| Tamai, Y | 1 |
| Ishii, R | 1 |
| Tamaki, S | 1 |
| Wake, A | 1 |
| Tajika, K | 1 |
| Sakai, R | 1 |
| Kobayashi, T | 1 |
| Hua, J | 1 |
| Inoue, M | 1 |
| Aisa, Y | 1 |
| Fujisawa, S | 1 |
| Miyazaki, K | 1 |
| Irie, S | 1 |
| Tanaka, E | 1 |
| Higashihara, M | 1 |
| Kumar, S | 1 |
| Moreau, P | 2 |
| Hari, P | 1 |
| Mateos, MV | 2 |
| Ludwig, H | 1 |
| Shustik, C | 1 |
| Masszi, T | 1 |
| Spencer, A | 1 |
| Hájek, R | 1 |
| Romeril, K | 1 |
| Avivi, I | 1 |
| Liberati, AM | 1 |
| Minnema, MC | 2 |
| Einsele, H | 1 |
| Lonial, S | 2 |
| Berg, D | 1 |
| Lin, J | 1 |
| Gupta, N | 1 |
| Esseltine, DL | 2 |
| Richardson, PG | 2 |
| Egle, A | 1 |
| Steurer, M | 1 |
| Melchardt, T | 1 |
| Weiss, L | 1 |
| Gassner, FJ | 1 |
| Zaborsky, N | 1 |
| Geisberger, R | 1 |
| Catakovic, K | 1 |
| Hartmann, TN | 1 |
| Pleyer, L | 1 |
| Voskova, D | 1 |
| Thaler, J | 1 |
| Lang, A | 1 |
| Girschikofsky, M | 1 |
| Petzer, A | 1 |
| Greil, R | 1 |
| Trudel, S | 1 |
| Tessoulin, B | 1 |
| Jullien, M | 1 |
| Blin, N | 1 |
| Gastinne, T | 1 |
| Mahé, B | 1 |
| Dubruille, V | 1 |
| Bonnet, A | 1 |
| Lok, A | 1 |
| Chevallier, P | 1 |
| Peterlin, P | 1 |
| Garnier, A | 1 |
| Guillaume, T | 1 |
| Le Bourgeois, A | 1 |
| Le Gouill, S | 1 |
| Touzeau, C | 1 |
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 1 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 1 |
| Damaj, G | 1 |
| Yordanova, A | 1 |
| Hose, D | 1 |
| Neben, K | 1 |
| Witzens-Harig, M | 1 |
| Gütgemann, I | 1 |
| Raab, MS | 1 |
| Moehler, T | 1 |
| Goldschmidt, H | 1 |
| Schmidt-Wolf, IG | 1 |
| Hitz, F | 1 |
| Fischer, N | 1 |
| Pabst, T | 1 |
| Caspar, C | 1 |
| Berthod, G | 1 |
| Eckhardt, K | 1 |
| Berardi Vilei, S | 1 |
| Zucca, E | 1 |
| Mey, U | 1 |
| Ordi-Ros, J | 1 |
| Cosiglio, FJ | 1 |
| Katodritou, E | 1 |
| Vadikolia, C | 1 |
| Lalagianni, C | 1 |
| Kotsopoulou, M | 1 |
| Papageorgiou, G | 1 |
| Kyrtsonis, MC | 1 |
| Matsouka, P | 1 |
| Giannakoulas, N | 1 |
| Kyriakou, D | 1 |
| Karras, G | 1 |
| Anagnostopoulos, N | 1 |
| Michali, E | 1 |
| Briasoulis, E | 1 |
| Hatzimichael, E | 1 |
| Spanoudakis, E | 1 |
| Zikos, P | 1 |
| Tsakiridou, A | 1 |
| Tsionos, K | 1 |
| Anargyrou, K | 1 |
| Symeonidis, A | 1 |
| Maniatis, A | 1 |
| Terpos, E | 1 |
| Voelter, V | 1 |
| Kwak, JY | 1 |
| Ryoo, HM | 1 |
| Kim, YS | 1 |
| Moon, JH | 1 |
| Park, SK | 1 |
| Kim, SH | 2 |
| Jo, DY | 1 |
| Jun, HJ | 1 |
| Kim, KH | 1 |
| Lee, JO | 1 |
| Lee, JH | 1 |
| Lazaryan, A | 1 |
| Hussein, MA | 1 |
| Reu, FJ | 1 |
| Faiman, B | 1 |
| Habecker, B | 1 |
| Ann Karam, M | 1 |
| Reed, J | 1 |
| Hamilton, K | 1 |
| Waksman, J | 1 |
| Bruening, K | 1 |
| Srkalovic, G | 1 |
| Andresen, S | 1 |
| Kalaycio, M | 1 |
| Sweetenham, JW | 1 |
| Sobecks, R | 1 |
| Dean, R | 1 |
| Knight, R | 2 |
| Zeldis, JB | 2 |
| Baz, R | 1 |
| Morabito, F | 2 |
| Bringhen, S | 2 |
| Larocca, A | 2 |
| Wijermans, P | 2 |
| Victoria Mateos, M | 1 |
| Gimsing, P | 2 |
| Mazzone, C | 1 |
| Gottardi, D | 1 |
| Omedè, P | 1 |
| Zweegman, S | 3 |
| José Lahuerta, J | 1 |
| Zambello, R | 1 |
| Musto, P | 2 |
| Magarotto, V | 1 |
| Schaafsma, M | 2 |
| Oriol, A | 1 |
| Juliusson, G | 2 |
| Cerrato, C | 1 |
| Catalano, L | 2 |
| Gentile, M | 2 |
| Isabel Turel, A | 1 |
| Marina Liberati, A | 1 |
| Cavalli, M | 1 |
| Rossi, D | 1 |
| Passera, R | 1 |
| Rosso, S | 1 |
| Beksac, M | 2 |
| Cavo, M | 2 |
| Waage, A | 2 |
| San Miguel, J | 1 |
| Boccadoro, M | 3 |
| Sonneveld, P | 3 |
| Palumbo, A | 4 |
| Offidani, M | 2 |
| Chang, WJ | 1 |
| Kang, ES | 1 |
| Lee, ST | 1 |
| Kim, DW | 1 |
| Zago, M | 1 |
| Oehrlein, K | 1 |
| Rendl, C | 1 |
| Hahn-Ast, C | 1 |
| Kanz, L | 1 |
| Weisel, K | 1 |
| Vozella, F | 1 |
| Latagliata, R | 1 |
| Carmosino, I | 1 |
| Volpicelli, P | 1 |
| Montagna, C | 1 |
| Romano, A | 1 |
| Roberto, A | 1 |
| Finsinger, P | 1 |
| Mancini, M | 1 |
| Breccia, M | 1 |
| Oliva, E | 2 |
| Pawlyn, C | 1 |
| Gay, F | 3 |
| Roy, V | 1 |
| Ailawadhi, S | 1 |
| Mittelman, M | 1 |
| Filanovsky, K | 1 |
| Ofran, Y | 1 |
| Rosenbaum, H | 1 |
| Raanani, P | 1 |
| Braester, A | 1 |
| Goldschmidt, N | 1 |
| Kirgner, I | 1 |
| Herishanu, Y | 1 |
| Perri, C | 1 |
| Ellis, M | 1 |
| Oster, HS | 1 |
| Popat, R | 1 |
| Brown, SR | 1 |
| Flanagan, L | 1 |
| Hall, A | 1 |
| Gregory, W | 1 |
| Kishore, B | 1 |
| Streetly, M | 1 |
| Oakervee, H | 1 |
| Yong, K | 1 |
| Cook, G | 1 |
| Low, E | 1 |
| Cavenagh, J | 1 |
| Amato, RJ | 3 |
| Malya, R | 1 |
| Rawat, A | 1 |
| Hernandez-McClain, J | 1 |
| Saxena, S | 1 |
| Khan, M | 2 |
| Hasselbalch, HC | 1 |
| Birgens, H | 1 |
| Dufva, IH | 1 |
| Dalseg, AM | 1 |
| Brown, Pde N | 1 |
| Jensen, MK | 1 |
| Vangsted, A | 1 |
| Wiernik, PH | 1 |
| Lossos, IS | 1 |
| Tuscano, JM | 1 |
| Justice, G | 1 |
| Vose, JM | 1 |
| Cole, CE | 1 |
| Lam, W | 1 |
| McBride, K | 1 |
| Wride, K | 1 |
| Pietronigro, D | 1 |
| Takeshita, K | 1 |
| Ervin-Haynes, A | 1 |
| Habermann, TM | 1 |
| Ciolli, S | 1 |
| Petrucci, MT | 1 |
| Galimberti, S | 1 |
| Mele, G | 1 |
| Casulli, AF | 1 |
| Mannina, D | 1 |
| Piro, E | 1 |
| Pinotti, G | 1 |
| Palmieri, S | 1 |
| Callea, V | 1 |
| Baldini, L | 1 |
| Tosi, P | 1 |
| Di Raimondo, F | 1 |
| Weller, E | 1 |
| Jakubowiak, AJ | 1 |
| Jagannath, S | 1 |
| Raje, NS | 1 |
| Avigan, DE | 1 |
| Xie, W | 1 |
| Ghobrial, IM | 1 |
| Schlossman, RL | 1 |
| Mazumder, A | 1 |
| Munshi, NC | 1 |
| Vesole, DH | 1 |
| Joyce, R | 1 |
| Kaufman, JL | 1 |
| Doss, D | 1 |
| Warren, DL | 1 |
| Lunde, LE | 1 |
| Kaster, S | 1 |
| Delaney, C | 1 |
| Hideshima, T | 1 |
| Mitsiades, CS | 1 |
| Anderson, KC | 1 |
| Wang, M | 1 |
| Delasalle, K | 1 |
| Giralt, S | 1 |
| Alexanian, R | 1 |
| Schey, SA | 1 |
| Morgan, GJ | 1 |
| Ramasamy, K | 1 |
| Hazel, B | 1 |
| Ladon, D | 1 |
| Corderoy, S | 1 |
| Jenner, M | 1 |
| Phekoo, K | 1 |
| Boyd, K | 1 |
| Davies, FE | 1 |
| Kivivuori, SM | 1 |
| Anttila, P | 1 |
| Saloura, V | 1 |
| Grivas, PD | 1 |
| Pérez Persona, E | 1 |
| Mesa, MG | 1 |
| García Sánchez, PJ | 1 |
| González Rodríguez, AP | 1 |
| Kneppers, E | 1 |
| van der Holt, B | 2 |
| Kersten, MJ | 1 |
| Meijer, E | 1 |
| Huls, G | 1 |
| Cornelissen, JJ | 1 |
| Janssen, JJ | 1 |
| Huisman, C | 1 |
| Cornelisse, PB | 1 |
| Bruijnen, CP | 1 |
| Emmelot, M | 1 |
| Lokhorst, HM | 1 |
| Mutis, T | 1 |
| Khan, ML | 1 |
| Reeder, CB | 2 |
| Kumar, SK | 1 |
| Lacy, MQ | 1 |
| Reece, DE | 1 |
| Dispenzieri, A | 1 |
| Gertz, MA | 1 |
| Greipp, P | 1 |
| Hayman, S | 1 |
| Zeldenhurst, S | 1 |
| Dingli, D | 1 |
| Lust, J | 1 |
| Russell, S | 1 |
| Laumann, KM | 1 |
| Mikhael, JR | 1 |
| Leif Bergsagel, P | 1 |
| Fonseca, R | 1 |
| Vincent Rajkumar, S | 1 |
| Keith Stewart, A | 1 |
| Rajkumar, SV | 1 |
| Hulin, C | 1 |
| Leleu, X | 2 |
| Sucak, G | 1 |
| Pezzatti, S | 1 |
| Pégourié, B | 1 |
| Galli, M | 1 |
| Turesson, I | 1 |
| Kolb, B | 1 |
| Baldi, I | 1 |
| Rolke, J | 1 |
| Ciccone, G | 1 |
| Wetterwald, M | 1 |
| Lokhorst, H | 1 |
| Rodon, P | 1 |
| Gozzetti, A | 1 |
| Defina, M | 1 |
| Bocchia, M | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Fenk, R | 2 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
| Micol, JB | 1 |
| Guieze, R | 1 |
| Berthon, C | 1 |
| Kuhnovsky, F | 1 |
| Terriou, L | 1 |
| Moreau, AS | 1 |
| Yakoub-Agha, I | 1 |
| Bauters, F | 1 |
| Facon, T | 1 |
| Sekeres, MA | 1 |
| List, A | 1 |
| Strupp, C | 1 |
| Germing, U | 1 |
| Aivado, M | 1 |
| Kündgen, A | 1 |
| Hünerlitürkoglu, A | 1 |
| Kobbe, G | 1 |
| Haas, R | 1 |
| Gattermann, N | 1 |
| Zou, YS | 1 |
| Fink, SR | 1 |
| Stockero, KJ | 1 |
| Paternoster, SF | 1 |
| Smoley, SA | 1 |
| Tun, HW | 1 |
| Tefferi, A | 1 |
| Dewald, GW | 1 |
| Parker, PM | 1 |
| Chao, N | 1 |
| Nademanee, A | 1 |
| O'Donnell, MR | 1 |
| Schmidt, GM | 1 |
| Snyder, DS | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Stepan, DE | 1 |
| Kashyap, A | 1 |
| Planas, I | 1 |
| Spielberger, R | 1 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Negrin, RS | 1 |
| Long, GD | 1 |
| Niland, JC | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.[NCT00738829] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.[NCT00987493] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)[NCT00091624] | Phase 1 | 77 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma[NCT00179660] | Phase 2 | 50 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00378105] | Phase 1/Phase 2 | 68 participants (Actual) | Interventional | 2006-09-30 | Active, not recruiting | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The duration of response was calculated as the first response assessment demonstrating evidence of at least a partial response to the first documentation of progressive disease (as determined by computed tomography scan) or death due to NHL, whichever occurred first. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate. (NCT00179660)
Timeframe: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 10.2 |
The duration of tumor control was calculated as the time from the first response assessment demonstrating at least stable disease to the first documentation of progressive disease or death due to NHL. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate. (NCT00179660)
Timeframe: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 6.0 |
"Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator.~CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.~Cru: Criteria for CR above but with 1 or more of the following:~A residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of diameters (SPD)~Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia).~PR: 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD." (NCT00179660)
Timeframe: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 34.7 |
"Tumor control was defined as participants with a complete response, unconfirmed complete response, partial response or stable disease (SD), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator.~SD was defined as a response less than a PR (see above) but not Progressive Disease (PD).~PD was defined as~≥ 50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or non-responders.~Appearance of any new lesion during or at the end of therapy." (NCT00179660)
Timeframe: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 59.2 |
"Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first.~Participants who withdrew for any reason or received another NHL therapy including stem cell transplantation without documented progressive disease were censored on the date of their last adequate response assessment indicating no progression (or last adequate assessment prior to receiving other NHL therapy). Participants who were still active without progressive disease at the time of the data cut-off date were censored on the date of their last adequate response assessment." (NCT00179660)
Timeframe: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.6 |
"The Investigator determined the relationship between the administration of study drug and the occurrence of an AE as suspected if the temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other drugs, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event.~The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria and the following scale:~Grade 1 = Mild~Grade 2 = Moderate~Grade 3 = Severe~Grade 4 = Life threatening~Grade 5 = Death~A Serious AE is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event." (NCT00179660)
Timeframe: From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 15.2 months.
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Adverse event related to study drug | Grade 3-5 adverse event | Grade 3-5 adverse event related to study drug | Serious adverse event | Serious adverse event related to study drug | AE leading to discontinuation of study drug | Related AE leading to study drug discontinuation | AE leading to dose reduction or interruption | |
| Lenalidomide | 49 | 42 | 36 | 27 | 21 | 6 | 9 | 4 | 28 |
Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died. (NCT00378105)
Timeframe: Survival rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 97 |
"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:~>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or >25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).~PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free" (NCT00378105)
Timeframe: PFS rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 75 |
Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria. (NCT00378105)
Timeframe: Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1 Population | 100 |
| Phase II Population | 100 |
| Total | 100 |
Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died. (NCT00378105)
Timeframe: Response rate at 18 months
| Intervention | Percentage of participants (Number) |
|---|---|
| All Patients | 68 |
11 reviews available for thalidomide and Blood Diseases
| Article | Year |
|---|---|
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End | 2014 |
Nuances in the Management of Older People With Multiple Myeloma.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Dexamethasone; | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2008 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2009 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestina | 2010 |
[Thalidomide in oncological and hematological diseases].
Topics: Angiogenesis Inhibitors; Female; Hematologic Diseases; Humans; Multiple Myeloma; Neoplasms; Pregnanc | 2010 |
Lenalidomide: a synthetic compound with an evolving role in cancer management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Di | 2010 |
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.
Topics: Aged; Aged, 80 and over; Female; Hematologic Diseases; Humans; Male; Multiple Myeloma; Randomized Co | 2013 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Foreca | 2005 |
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Topics: Aged; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Female; Hematologic D | 2005 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
19 trials available for thalidomide and Blood Diseases
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidati | 2018 |
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2014 |
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di | 2008 |
Lenalidomide therapy for metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2008 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2010 |
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-R | 2010 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cycl | 2011 |
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
18 other studies available for thalidomide and Blood Diseases
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2019 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex | 2014 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome A | 2014 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cycl | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic | 2015 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2010 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2010 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2011 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Mu | 2012 |
Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.
Topics: Antineoplastic Agents; Disease Management; Hematologic Diseases; Humans; Lenalidomide; Randomized Co | 2012 |
Lenalidomide maintenance in myeloma.
Topics: Antineoplastic Agents; Disease Management; Hematologic Diseases; Humans; Thalidomide | 2012 |
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymp | 2005 |
Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Cytogenetic Analy | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders.
Topics: Hematologic Diseases; Humans; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis | 2002 |